Category: Press Release - Page 42 - Psychedelic Alpha

Read more about the article atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology

atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology

Post published:October 19, 2022
Post category:Press Release

Read more about the article Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics

Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics

Post published:October 19, 2022
Post category:Press Release

Read more about the article Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform to Advance Pipeline of Neuroactive Compounds Targeting CNS Disorders

Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform to Advance Pipeline of Neuroactive Compounds Targeting CNS Disorders

Post published:October 18, 2022
Post category:Press Release

Read more about the article Small Pharma Reports Fiscal Second Quarter 2023 Highlights

Small Pharma Reports Fiscal Second Quarter 2023 Highlights

Post published:October 15, 2022
Post category:Press Release

Read more about the article Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

Post published:October 15, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference

Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference

Post published:October 15, 2022
Post category:Press Release

Read more about the article atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD

atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD

Post published:October 13, 2022
Post category:Press Release

Read more about the article FILAMENT HEALTH TO HOST VIRTUAL INVESTOR UPDATE

FILAMENT HEALTH TO HOST VIRTUAL INVESTOR UPDATE

Post published:October 13, 2022
Post category:Press Release

Read more about the article Reunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives on Psychedelics Conference

Reunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives on Psychedelics Conference

Post published:October 12, 2022
Post category:Press Release

Read more about the article COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day

COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day

Post published:October 12, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.